Clinical Trial Update: Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of Sunphenon EGCg (Epigallocatechin-Gallate) in early-stage Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Sunphenon EGCg (Epigallocatechin-Gallate)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: COMPLETED